RECRUITING

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Description

Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned study intervention or continue their follow-up visits by transitioning to this study. This study will evaluate the long-term safety and efficacy of pirtobrutinib.

Conditions

Chronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma
Talk to us

Related Conditions:

Chronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma

Study Overview

On this page

Study Details

Study overview

Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned study intervention or continue their follow-up visits by transitioning to this study. This study will evaluate the long-term safety and efficacy of pirtobrutinib.

Long-Term Safety of Pirtobrutinib in Participants From Study LOXO-BTK-18001 With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Condition
Chronic Lymphocytic Leukemia
Intervention / Treatment

-

Contacts and Locations

Miami

Sylvester Comprehensive Cancer Center, Miami, Florida, United States, 33136-1002

Sarasota

Florida Cancer Specialists, Sarasota, Florida, United States, 34232-6422

Atlanta

The Emory Clinic, Atlanta, Georgia, United States, 30322-1013

Chicago

Northwestern University, Chicago, Illinois, United States, 60611-3013

Boston

Dana-Farber Cancer Institute, Boston, Massachusetts, United States, 02115

Rochester

Mayo Clinic- Minnesota, Rochester, Minnesota, United States, 55905

Omaha

University Of Nebraska Medical Center, Omaha, Nebraska, United States, 69198

Ithaca

Cayuga Cancer Center, Ithaca, New York, United States, 14850

Lake Success

Northwell Health, Lake Success, New York, United States, 11042-1118

New York

Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York, New York, United States, 10065-6007

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Are currently enrolled and active in the originator study, 18001. A participant is considered active in the study if they are:
  • * receiving study intervention
  • * in the short-term follow-up period, or
  • * in the long-term follow-up period.
  • * Were a participant in the Phase 1b cohort of Study 18001.
  • * Are pregnant or intend to become pregnant during the study or within 30 days of last dose of study treatment or intend to breastfeed during the study or within 1 week of the last dose of study treatment.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Eli Lilly and Company,

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), STUDY_DIRECTOR, Eli Lilly and Company

Study Record Dates

2032-12